Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
EGFR: early-phase trial registry
3 of 4 indexed EGFR trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
EGFR: 4 US clinical trials tracked, 3 recruiting.
EGFR is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is TOLREMO therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition egfr
OPEN 3 | RECR 75% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
EGFR lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for EGFR on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
EGFR is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology
NCT06960395
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Taiho Oncology
NCT07128199
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
TOLREMO therapeutics
NCT06403436
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
University of Virginia
NCT05370469
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on EGFR records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on EGFR trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this EGFR page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 EGFR trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- TOLREMO therapeutics sponsors the most EGFR trials on record, review their full trial history before evaluating a specific study. See TOLREMO therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This EGFR condition card totals 4 registered trials; most-linked intervention Fitbit Sense; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.